噬菌体及其组分疗法对临床微生物实验室的意义
本综述检索了2007年1月至2019年3月关于噬菌体及噬菌体编码蛋白疗法的文献,探讨其作为应对细菌耐药问题的潜在替代策略。文章指出临床微生物学家应熟悉噬菌体及其抗菌组分,并特别了解相关检测方法,以应对这类疗法可能进入临床的趋势。
要点
- 噬菌体疗法是应对细菌耐药的有前景策略之一。
- 临床微生物实验室需熟悉噬菌体及其抗菌组分的检测方法。
- 噬菌体疗法可能扩展进入临床医学,需提前准备。
核心结论
- 噬菌体及噬菌体组分疗法是有前景的抗菌策略,临床微生物学家应熟悉其检测方法。
研究设计与样本
- 综述检索2007年1月至2019年3月与临床微生物相关的噬菌体及噬菌体编码蛋白疗法文献。
主要发现
- 现有抗菌药物活性下降且持续选择耐药,需确定新的细菌感染管理策略。
- 噬菌体疗法被视为有前景的方法之一。
临床怎么用
- 临床微生物学家应熟悉噬菌体及其抗菌组分,并了解检测它们的方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of bacterial infections is increasingly challenged by resistance to currently available antibacterial agents. Not only are such agents less likely to be active today than they were in the past, but their very use has selected for and continues to select for further resistance. Additional strategies for the management of bacterial illnesses must be identified. In this review, bacteriophage-based therapies are presented as one promising approach. In anticipation of their potential expansion into clinical medicine, clinical microbiologists may wish to acquaint themselves with bacteriophages and their antibacterial components and, specifically, with methods for testing them. Here, we reviewed the literature spanning January 2007 to March 2019 on bacteriophage and phage-encoded protein therapies of relevance to clinical microbiology.
引用
- Caflisch KM, Patel R. Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory. J Clin Microbiol. 2019. PMID: 31092596. doi:10.1128/JCM.00229-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。